21
Î Patients and close contacts should be advised to use anti-lice lotion
and shampoo for non-ocular areas and to wash and dry clothing and
bedding thoroughly. (III, G, S)
Î Patients and sexual contacts should be informed about the possibility
of concomitant disease and should be referred appropriately. (III, G, S)
Î Sexual abuse should be considered in children with this condition.
(III, I, D)
Medication-Induced Keratoconjunctivitis
Î Discontinuation of the agent responsible for medication-induced
keratoconjunctivitis results in resolution over a period of weeks to
months. (III, I, D)
Î If severe inflammation of the conjunctiva or eyelid is present, a brief
course of topical corticosteroids is indicated. (III, I, D)
Î Nonpreserved artificial tears may be beneficial. (III, I, D)
Î The clinician should look for sub-epithelial fibrosis. (III, I, D)
Adenoviral Conjunctivitis
Î The majority of cases of acute, infectious conjunctivitis in the adult
population are viral and self-limited. These cases do not require
antibiotic treatment. (III, I, D)
Î Patients with adenoviral conjunctivitis need to understand that the
condition is highly contagious and should be informed of appropriate
measures to reduce the risk of spreading the infection to their other
eye or to other people. (III, G, S)
Î Artificial tears, topical antihistamines, or cold compresses may be
used to mitigate symptoms of adenoviral conjunctivitis. (III, I, D)
Î There is inadequate evidence to support the use of available antiviral
agents for treating adenoviral conjunctivitis. (III, I, D)
Î Topical corticosteroids are helpful to reduce symptoms and may
reduce scarring in severe cases of adenoviral keratoconjunctivitis with
marked chemosis or lid swelling, epithelial sloughing, or membranous
conjunctivitis. (III, I, D)
Î Close follow-up is warranted for patients with adenoviral conjunctivitis
who are being treated with corticosteroids. (III, I, D)
Î Patients who use topical corticosteroids should be instructed to
maintain precautions against the spread of the virus for 2 additional
weeks after symptoms resolve. (III, I, D)
